Both drugs found to have similar cancer incidence lowering effect with robust studies. Dew, you posted on that one as well.(update edit: and I see your comments as well as DrBio's--thanks)
Given the symptom reduction that both drugs provide (for BPH) will this class of drugs become a standard of care for men over age 50? As there are many here that fit that cohort (and I'm moving closer to that 50 year hurdle and tolerance limit with BPH symptoms), I'd like to hear opinions as to the worth of this lifelong treatment.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.